96.5 F
San Fernando
Thursday, Mar 28, 2024

Amgen Licenses Cancer Fighter

Amgen has obtained an exclusive license to develop and commercialize a cancer-fighting antibody generated by Tokyo-based company Kyowa Hakko Kogyo Co. Ltd. The licensing agreement stipulates that Amgen will make an upfront payment to Kyowa Hakko of $100 million. Kyowa Hakko could receive up to $420 million in additional payments and will also be entitled to receive double digit royalties on sales. Amgen’s 2008 adjusted earnings per share will not be affected by this transaction. The agreement will be effective once it is approved by the Federal Trade Commission.

Featured Articles

Related Articles